Highlights
- FY26 gross Revenue expected to exceed $7.4m, up 27% YoY and 14% above prior guidance
- Expansion driven by strong New Zealand retail growth + new Southeast Asia distribution deal
- EBITDA loss projected to fall below $1.6m, improving 25% vs FY25
Overview
Me Today (NZX:MEE) has upgraded its FY26 outlook, signaling stronger-than-expected revenue momentum and improving cost efficiency. The company now anticipates gross revenue above $7.4 million, reflecting robust growth of 27% year-on-year and a meaningful uplift from earlier guidance. This performance is underpinned by accelerating Demand in New Zealand, where expanded retail shelf space and new product launches have significantly boosted sales. Internationally, the Business is entering a new phase of growth with a distribution agreement across Southeast Asia, starting with Singapore.
At the same time, disciplined cost management and operational focus are expected to reduce EBITDA losses to below $1.6 million, marking a 25% improvement on the prior year despite continued Investment in Brand and product innovation.
NZ Growth & Product Expansion Driving Momentum
The New Zealand market remains the core growth engine for Me Today, supported by stronger visibility across major retail partners following a new planogram rollout. This has directly contributed to a reported 113% increase in retail sales within its largest NZ channel. Growth is further reinforced by an aggressive product innovation strategy, with 15 new launches in FY26, including herbal liquids, capsules, sprays, and functional powder blends. The brand is also expanding into new wellness formats, strengthening its position in the competitive health supplements space.
Southeast Asia Expansion & Global Reach Strategy
Me Today has secured a key milestone with an exclusive distribution agreement across Singapore, Malaysia, Thailand, and Vietnam, marking a strategic entry into high-growth Asian wellness markets. Singapore will serve as the initial launchpad, supported by early purchase orders and regional Marketing activation. Regulatory approvals for other markets are expected through 2027, indicating a phased expansion strategy. Alongside Asia, the company continues to build presence in the US, Japan, Ireland, and the UAE, with Manuka honey-led sales in the US already exceeding NZD $1.04m in FY26.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
This report (“Report”) has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this Report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).
The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not issue, sell or deal in any financial products. The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes.
Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Report, or its content, may be reproduced in any form without our prior consent.